Navigation Links
Exelixis Announces First Quarter 2008 Financial Results

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter ended March 31, 2008.

Revenues for the quarter ended March 31, 2008 were $27.9 million, compared to $28.1 million for the comparable period in 2007. Revenues for 2008 were generally consistent with 2007, but reflect the completion of revenue recognition associated with our collaboration with Daiichi Sankyo Company Limited for our Mineralocorticoid Receptor (MR) program and the exclusion of revenue of our former subsidiary Artemis Pharmaceuticals GmbH, which is no longer consolidated as a result of the sale of 80.1% of our ownership in 2007. These items were offset by the revenue recognition associated with our collaborations with Bristol-Myers Squibb Company for various oncology programs and with Genentech, Inc. for the co-development of our MEK inhibitor XL518.

Research and development expenses for the quarter ended March 31, 2008 were $66.0 million, compared to $50.2 million for the comparable period in 2007. The increase from 2007 to 2008 primarily reflects the increased development expenses associated with the continued advancement and expansion of our clinical trial activity.

General and administrative expenses for the quarter ended March 31, 2008 were $8.7 million, compared to $11.2 million for the comparable period in 2007. The decrease from 2007 to 2008 was primarily due to the allocation of general corporate costs (such as facilities costs) to research and development, which primarily reflects the growth of the research and development function compared to the general and administrative function.

Net loss for the quarter ended March 31, 2008 was $41.3 million, or $0.39 per share, compared to $24.2 million, or $0.25 per share, for the comparable period in 2007. The increase in net loss from 2007 to 2008 was primarily due to the increase in the research and development activity described above.

Cash and cash equivalents, short-term and long-term marketable securities, investments held by Symphony Evolution, Inc. (a consolidated clinical development financing vehicle) and restricted cash and investments totaled $252.2 million at March 31, 2008, compared to $299.5 million at December 31, 2007.

Q1 2008 Highlights and Recent Developments

-- Genentech exercised its option to develop and commercialize our

compound XL518, a selective and potent inhibitor of MEK, which is

currently in a phase 1 clinical trial. Selection of the compound and

opt-in by Genentech triggered a payment of $3.0 million. Another

$7.0 million is due when a phase 2 program is initiated by Genentech.

-- Bristol-Myers Squibb exercised its option to develop and commercialize

our compound XL139, an inhibitor of the hedgehog signaling pathway, for

which we received a $20.0 million selection milestone in February 2008.

In addition, we exercised our option under the collaboration agreement

to co-develop and co-commercialize XL139 in the United States.

-- Data from clinical trials of our investigational compounds XL647,

XL184, XL765, and XL880* will be presented at the 2008 American Society

of Clinical Oncology (ASCO) Annual Meeting, which will be held from

May 30 to June 3 in Chicago, Illinois. The clinical trial data will be

described in two oral presentations (XL184 and XL765), two poster

discussion presentations (XL647) and three poster presentations (XL647

and XL880*).

* The technology transfer by Exelixis to GlaxoSmithKline (GSK) in

connection with GSK's election to further develop and commercialize

XL880 was completed during the first quarter 2008.

"This year's ASCO promises to be a significant event for Exelixis," said George A. Scangos, PhD, president and chief executive officer of Exelixis, Inc. "We will make seven presentations, which is our largest presence at ASCO to date, and we will provide a wealth of new data on four of our lead compounds. We believe this data will meaningfully differentiate our compounds from the competition. With the number of abstracts selected for presentation at ASCO and six selections by partners, the quality of our compounds is being increasingly recognized and validated."

Conference Call and Webcast

Exelixis' management will discuss the company's first quarter ended March 31, 2008 financial results as well as a general update on the company's financial position and business, including its development pipeline and corporate strategy, during a conference call beginning at 2:00 p.m. PT/ 5:00 p.m. ET today, Tuesday, May 6, 2008. To listen to a webcast of the discussion, visit the Event Calendar page under Investors at

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to the future development and potential efficacy of our compounds, our partners' decisions under their respective collaborations with us, and the impact of new data to be presented on our compounds. Words such as "hope," "plan," "may," "expect," "continue," "believe," "when," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the potential failure of our compounds to demonstrate safety and efficacy in clinical testing, our relationship with our partners, our ability to enter into new collaborations, continue existing collaborations and receive milestones and royalties under our collaborative agreements, the timing and level of expenses associated with the growth of proprietary programs and other collaborations, the ability to co-develop and generate revenues under collaborations with our partners, our ability to meet industry expectations with data from clinical trials involving any of our compounds, and the therapeutic and commercial value of our compounds. These and other risk factors are discussed under "Risk Factors" and elsewhere in our quarterly report on Form 10-Q for the quarter ended March 31, 2008, and other filings with the Securities and Exchange Commission. We expressly disclaim any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Exelixis and the Exelixis logo are registered U.S. trademarks.

- see attached financial tables -



(in thousands, except per share data)


Three Months Ended

March 31,

2008 2007


Contract $18,626 $15,166

License 9,318 12,970

Total revenues 27,944 28,136

Operating expenses:

Research and development 65,973 50,210

General and administrative 8,691 11,211

Amortization of intangibles -- 72

Total operating expenses 74,664 61,493

Loss from operations (46,720) (33,357)

Other income (expense):

Interest income and other, net 2,511 3,594

Interest expense (961) (1,027)

Total other income 1,550 2,567

Loss before noncontrolling interest in

Symphony Evolution, Inc. (45,170) (30,790)

Loss attributed to noncontrolling interest in

Symphony Evolution, Inc. 3,896 6,589

Net loss $(41,274) $(24,201)

Net loss per share, basic and diluted $(0.39) $(0.25)

Shares used in computing basic and diluted

net loss per share 104,993 96,411



(in thousands)

March 31, December 31,

2008 2007 (1)


Cash and cash equivalents and short-term

and long-term marketable securities (2) $252,237 $299,530

Working capital $113,063 $150,898

Total assets $370,572 $412,120

Stockholders' equity $39,860 $72,081

(1) Derived from the audited consolidated financial statements.

(2) These amounts include investments held by Symphony Evolution, Inc. of

$27.6 million and $30.9 million and restricted cash and investments of

$5.3 million and $7.2 million as of March 31, 2008 and December 31,

2007, respectively.

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... DC (PRWEB) , ... May 26, 2016 , ... There ... National Hot Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight ... dogs, 63 percent say grilling is their favorite way to cook a hot dog, ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... discovery of thousands of defective respirators, according to court documents and SEC filings. ... of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... ... On Memorial Day, Hope For Heroes and USA Medical Card will ... country. The nonprofit Hope For Heroes partnered with the leading provider of free ... military veterans, as well as police, firemen, and EMS professionals across the country, and ...
Breaking Medicine News(10 mins):